BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:06 PM
 | 
Jul 20, 2009
 |  BC Extra  |  Clinical News

Exenatide once weekly meets endpoint

Late on Monday, Amylin Pharmaceuticals Inc. (NASDAQ:AMLN), Eli Lilly and Co. (NYSE:LLY) and Alkermes Inc. (NASDAQ:ALKS) said exenatide once weekly met the primary endpoint of significantly decreasing HbA1c from baseline to week 26 compared to daily

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >